4.52 USD
▼-0.07-1.53%
盘后 4.45 -1.55%
2026-09-15
市值
$460.39M
市盈率
—
EPS
-0.72
股息率
—
52 周区间
0.98 – 6.83
成交量
262.71K
Beta
0.96
目标价
8.00
52W 低 0.9852W 高 6.83
价格走势
公司简介
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCel...